BioLineRx Ltd. (BLRX) Form 6-K — Jul 8, 2026
BioLineRx and partner Hemispherian announced positive preclinical data showing strong synergy between GLIX1 and the PARP inhibitor olaparib in ovarian cancer models. The combination therapy demonstrated tumor reduction comparable to the chemotherapy benchmark cisplatin, outperforming control and monotherapy arms even at lower doses.
Key figures
- Clinical Trial Id
- NCT07464925
- Hr Proficient Percentage
- 50%
- Phase1 2a Part1 Patients
- up to 30
- Ovarian Cancer Deaths2026
- 12450
- Ovarian Cancer New Cases2026
- 21000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.